Benzinga's Top Pre-Market Losers
Nektar Therapeutics (NASDAQ: NKTR) dipped 24.19% to $10.50 in the pre-market session after the company reported that the results from Phase 2 trial of NKTR-181 missed primary efficacy endpoint.
Zoltek Companies (NASDAQ: ZOLT) shares dropped 10.05% to $16.65 in pre-market trading after Toray Industries agreed to buy Zoltek Companies for $16.75 per share.
J. C. Penney Company (NYSE: JCP) shares fell 8.54% to $9.53 in the pre-market trading after the company priced its underwritten public offering of 84.0 million shares of its common stock at $9.65 per share.
Accenture (NYSE: ACN) dipped 4.18% to $72.70 in the pre-market session after the company reported a rise in its fiscal fourth-quarter net income. For the current fiscal year, the company projected net income of $4.42 to $4.54 per share, versus analysts' expectations of $4.50 per share.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.